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Summary 
In order to determine whether atrial natriuretic hormone (ANH)  secretion is al- 
tered in diabetic patients with autonomic neuropathy,  plasma immunoreactive A N H  
( IR-ANH)  levels were measured in 23 patients with insulin-dependent diabetes mel- 
litus, 12 of  whom had definite cardiac autonomic neuropathy determined by non- 
invasive maneuvers. Levels were also measured in 31 healthy control subjects. 
Whereas only one of  the 11 diabetics without cardiac autonomic neuropathy had 
elevated I R - A N H  levels, four of  the 12 diabetics with cardiac autonomic neuropathy 
had elevated I R - A N H  levels (P = 0.03 compared to control subjects). 24-h urinary 
sodium excetion was not different among the groups. There was no significant cor- 
relation between I R - A N H  levels and diabetes control and any of  the parameters  of  
autonomic nervous system activity nor between I R - A N H  levels and plasma norepi- 
nephrine or epinephrine levels. Furthermore,  no relationship was observed in the 
diabetic subjects between I R - A N H  levels and left ventricular ejection fraction deter- 
mined by radionuclide ventriculography. Thus, elevated I R - A N H  levels occur with 
greater frequency in diabetic patients with autonomic neuropathy. These elevations 
do not appear  to be due to alterations in dietary sodium intake or left ventricular 
dysfunction. 
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Introduction 
Specific protein-containing granules have been observed in mammalian atria [1,2] 
and the number of granules present in the heart varies with changes in vascular 
volume and composition [3]. These granules contain a group of vasoactive, natriuretic 
peptides that have been collectively termed the atrial natriuretic factor (ANF) [4,5]. 
With the recent report of measurable ANF levels in human plasma [6-8] and the 
description of membrane receptors for ANF in arterial smooth muscle, renal [9], and 
adrenal cortical tissue [10], a role for ANF as a circulating hormone seems assured. 
In this regard, we believe the term atrial natriuretic hormone (ANH) is more appro- 
priate. 
The mechanisms whereby ANH secretion occur are speculative. It has been sug- 
gested that increased atrial stretch may directly result in ANH secretion [11-13]. 
Whether neural or hormonal stimulation of ANH secretion occurs is unknown, but 
previous observations suggest that these mechanisms may be functioning in the reg- 
ulation of ANH secretion. Areas of the cardiac atria that are very sensitive to small 
changes in atrial stretch are richly supplied with nerve endings from the autonomic 
nervous system [14]. Changes in the number of atrial granules have been observed 
following manipulations of autonomic nervous system activity [15,16]. Recently, ad- 
renergic and cholinergic agonists have been shown to stimulate ANH release in vitro 
[17,18] and in vivo [19]. 
A dysautonomia involving cholinergic and adrenergic systems develops in many 
patients with diabetes mellitus [20] and may be detected and graded by cardiovascular 
reflex tests [21,22] and plasma catecholamine levels [23]. As part of an ongoing study 
on the relationship between the autonomic nervous system and cardiovascular disease 
in diabetes mellitus, we have characterized autonomic nervous system activity and 
left ventricular performance in a number of subjects with diabetes meUitus [24]. In 
order to investigate whether a relationship exists between ANH and autonomic ner- 
vous system activity or left ventricular performance, we have measured immuno- 
reactive-ANH (IR-ANH) in the plasma of subjects with diabetes mellitus. We report 
here that IR-ANH levels are elevated among some patients with diabetes mellitus, 
particularly in those with autonomic neuropathy. The mechanism of release and 
importance of the elevated circulating hormone levels needs to be determined. 
Methods 
Subjects 
Nineteen male and 12 female normotensive healthy volunteers, aged 19 to 39 years, 
consuming a regular diet were studied. Blood was drawn from the subjects in the 
recumbent position through a butterfly needle. A urine sample for sodium and cre- 
atinine was collected during the 24 h preceding the venous sampling. Due to incom- 
plete urine collections in 6 of the control subjects, urinary data from only 25 of them 
were included. 
Seven male and 16 female subjects, 19 to 44 years old, with insulin-dependent 
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diabetes mellitus (duration 10 to 28 years) were studied in a manner similar to that 
of  controls. Criteria for selection included a blood pressure < 140/90 mm Hg without 
therapy, a creatinine clearance > 75 ml/min and a serum creatinine level < 1.5 mg/dl, 
no clinical evidence of  congestive heart failure (gallop rhythm, rales, neck vein dis- 
tention), and no peripheral edema of  any cause. All medications other than insulin 
were discontinued 24 h prior to study. All patients were in sinus rhythm. 
Samples were drawn into EDTA tubes, placed on ice, and plasma was separated 
within 15 min of  sampling. Plasma samples for IR-ANH were stored at -70"C.  
Assay methods 
Measurement of  IR-ANH was performed as described by Shenker et al. [6]. Briefly, 
plasma was extracted through C18 cartridges (Sep-Pak; Waters Associates, Milford, 
MA), eluted, and air-dried overnight. Synthetic A N H  standard (atriopeptin III) and 
antibody against 1-28 alpha human atrial natriuretic peptide were purchased from 
Peninsula Laboratories, Inc., (Belmont, CA), and 125I-atriopeptin III was prepared 
using a chloramine-T procedure. Following an 18 h incubation, free and bound hor- 
mone were separated using dextran charcoal. Recovery of  synthetic atriopeptin III 
was 56.6 4- 2.4%. Plasma levels of AN H  were calculated in pmol/l after correction 
for recovery. Intraassay variation was 8.5% and interassay variation was 12.6%. 
Extent of cardiac autonomic neuropathy 
Patients were tested for cardiac autonomic neuropathy using five non-invasive 
indices of  autonomic function [21,22]. The response to each test of  autonomic func- 
tion was graded as normal or abnormal and patients were assigned an autonomic 
function score from 0 to 5 based on the sum of  the number of  abnormal tests. A 
subject was classified as having definite cardiac autonomic neuropathy if two or more 
tests were abnormal as suggested by Ewing et al. [22]. The screen consisted of: 
(1) Resting pulse. This was determined by examination of  an electrocardiograph- 
ic tracing after the subjects had been lying supine for 15 min. Abnormal was defined 
as- > 100 beats/min. 
(2) Beat to beat heart rate variability. This was determined with the subject lying 
quietly and breathing deeply at 6 breaths per min. The difference between the mini- 
mum and maximum heart rate was determined by electrocardiographic tracings over 
1 min. Abnormal was defined as < 10 beats/min. 
(3) Valsalva maneuver. Subjects blew into a manometer  to maintain a pressure 
of  40 mm Hg for 15 sec during continuous electrocardiographic monitoring. The 
ratio of the longest R-R interval after the maneuver to the shortest R-R interval 
during the maneuver was calculated. Abnormal was defined as < 1.10. 
(4) Heart rate response to standing. During continuous electrocardiographic 
monitoring, the ratio of  the R-R interval of  the 30th beat after standing compared 
to the R-R interval at the 15th beat (30:15 ratio) was calculated. Abnormal was 
defined as < 1.02. 
(5) Blood pressure response to standing. The fall in systolic blood pressure after 
1 min of  standing was determined using cuff sphygrnomanometry. Abnormal was 
defined as > 30 mm Hg. 
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Equilibrium radionuclide ventriculography 
Gated blood pool scintigraphy was performed with the subjects in the supine posi- 
tion using the in vivo labeling method with 25 mCi of technetium-99m pertechnetate. 
Imaging was accomplished using a conventional Anger camera equipped with a high 
sensitivity parallel-hole collimator interfaced to a dedicated minicomputer system. 
The left anterior oblique projection that best isolated the left ventricle was used. The 
data were digitized to a 64 x 64 pixel matrix for subsequent analysis and the cardiac 
cycle was formatted into 32 frames. Data acquisition was terminated after 300000 
counts per frame were obtained. In our facility a normal left ventricular ejection 
fraction is > 50%. 
Determination of plasma catecholamines 
Blood samples were also collected after 30 min with the subject in the recumbent 
position. Plasma norepinephrine and epinephrine concentrations were measured in 
the University of Michigan Diabetes Research and Training Center Ligand Core 
Laboratory by the method of Peuler and Johnson [25]. 
Statistical methods 
Data were entered into the CLINFO database of the University of Michigan Clin- 
ical Research Center. Although the data are non-gaussian, they are expressed as 
mean + S.E. for the sake of comparison. IR-ANH levels in the diabetic patients 
were compared to levels in the control subjects using the Wilcoxon rank sum test and 
Fisher's exact test. Spearman rank correlations were used to determine if a correlation 
existed between IR-ANH and other variables. 
Experimental results 
Twelve of the 23 subjects with diabetes mellitus had definite cardiac autonomic 
neuropathy, but did not differ from the eleven diabetics without cardiac autonomic 
neuropathy with regard to age, duration of diabetes or urinary sodium or creatinine 
(Table I). Urinary sodium in control and diabetic subjects was similar. Recumbent 
catecholamine levels were not significantly different between the two groups of dia- 
betic subjects and were within the normal range [23]. 
IR-ANH was detectable in all plasma samples. In the healthy volunteers IR-ANH 
levels ranged from 1.0 to 46.0 pmol/l (Fig. 1). Among diabetic patients without car- 
diac autonomic neuropathy IR-ANH levels ranged from 8 to 58 pmol/1, and in the 
diabetic patients with cardiac autonomic neuropathy levels ranged from 5 to 97 
pmol/1. There were no significant differences between the mean values of the two 
patient groups and the control subjects (Table I). Five of the 23 diabetic subjects had 
IR-ANH levels that were more than 2 standard deviations above the mean level of 
the control subjects (P = 0.07). The clinical characteristics of the five diabetic patients 
with elevated IR-ANH levels are shown in Table II. Four of the 5 diabetic patients 
with elevated IR-ANH levels had definite cardiac autonomic neuropathy. The pres- 
ence of elevated IR-ANH levels in 4 of the 12 diabetic patients with cardiac auto- 
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TABLE I 
Characteristics of  diabetic patients and normal  control subjects 
Diabetic subjects Diabetic subjects Normal  controls 
without *CAN (n = 11) with C A N  (n = 12) (n = 31) 
Age (years) 36.1 ± 2.6 33.8 + 2.7 25.0 + 1.0 
Years diabetes 18.7 ± 1.6 16.7 + 2.4 - 
Urine sodium 
(mEq/24h)  153 + 18 168 + 11 186 ± 17 
I R - A N H  (pmol/l) 17.0 4- 4.4 27.5 ± 7.6 13.1 ± 1.6 
Data  are mean + S.E. 
* C A N  denotes cardiac autonomic neuropathy (see text for details). 
nomic neuropathy compared to one of  the 31 control subjects is significantly different 
(P = 0.03, Fisher's exact test), but is not significantly different from the presence of 
elevated levels in one of  the 11 diabetic patients without cardiac autonomic neuro- 
pathy (P = 0.31) (Fig. 1). There was no correlation between IR-ANH levels and the 
degree of glycemic control as evaluated by HbAI¢ levels. 
The correlations between IR-ANH levels and either the total autonomic function 
score (r = 0.29) or the individual tests of autonomic function (data not shown) were 
not significant (Fig. 2A). There was no significant relationship between IR-ANH 
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Fig. 1. Plasma levels o f  immunoreact ive atrial natriuretic hormone  ( IR-ANH) in 31 control subjects (solid 
boxes), 11 patients with diabetes mellitus without cardiac autonomic  neuropa thy  (open boxes) and 12 
patients with diabetes mellitus and cardiac autonomic  neuropathy  (diamonds).  Solid circles indicate mean  
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Fig. 2. (A) Scatter plot of immunoreactive atrial natriuretic hormone ( IR-ANH) against the autonomic 
function score (see text for details) (r = 0.30, P = 0.16). (B) Scatter plot of immunoreactive atrial natri- 
uretic hormone ( IR-ANH) against left ventricular ejection fraction (LVEF) (r = 0.22, P = 0.30). 
-0.18) levels. The relationship between IR-ANH levels and left ventricular ejection 
fraction is shown in Fig. 2B. 
Discussion 
We have measured circulating IR-ANH in the plasma of 23 diabetic subjects and 
have observed elevated levels in five of these subjects. Factors that might result in 
elevated IR-ANH levels are uncertain and there is little direct data regarding physio- 
logic regulation of ANH release. Studies demonstrating a diuresis [26] and natriuresis 
[27] following atrial distention led to investigation of the role of atrial distention in 
ANH secretion. Using a bioassay, Dietz [11] detected increased natriuretic activity 
in the effluent of rat heart-lung preparations following atrial distention. Lang et al. 
[12] observed that atrial distention in isolated rat hearts resulted in ANH release 
detected by radioimmunoassay, and Ledsome et al. [13] recorded similar observations 
in anaesthetized dogs. Our studies [6] and others [28] have demonstrated elevated 
IR-ANH levels in patients with left ventricular dysfunction. The degree of IR-ANH 
elevation was positively correlated with the severity of the left ventricular dysfunction 
in both studies [6,28], suggesting that the degree of atrial distention determines the 
ANH response in humans. 
Although intracardiac pressure determinations were not performed, elevated atrial 
pressure is an unlikely explanation for the increased IR-ANH levels observed in this 
study. Patients were free of edema, jugular venous distention and congestive heart 
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failure. Furthermore, 22 of the 23 subjects had normal global ventricular perform- 
ance by radionuclide ventriculography and no correlation between IR-ANH and 
ejection fraction was present (Fig. 2). The patient with the lowest ejection fraction 
had an IR-ANH level in the normal range. 
Although IR-ANH levels are increased by high sodium diet, it is unlikely that 
differences in diet were adequate to explain the observed elevations in IR-ANH as 
urinary sodium levels in the diabetic patients were not significantly different from 
those measured in controls (Table I). 
Previous work supports the concept that autonomic neuronal dysfunction might 
result in altered ANH secretion. Reserpine reduces atrial granularity [15] and beta- 
blockers can increase atrial granularity [16]. Recent investigations have demonstrated 
increased secretion of ANH from isolated rat atria exposed to epinephrine and ace- 
tylcholine [17,18], although these results have been questioned due to the absence of 
appropriate controls [29]. We have demonstrated that infusions of epinephrine in six 
normal subjects led to significant increases in plasma IR-ANH levels [19]. The plasma 
levels of epinephrine achieved during these infusions were much higher than those 
measured in the present study (Table II). The mechanism whereby catecholamines 
alter ANH secretion is unknown. 
Although cardiac autonomic neuropathy was detected in most of the patients with 
elevated IR-ANH levels, no significant relationship between IR-ANH levels and 
parameters of autonomic function could be established. It may be that there is no 
association between autonomic dysfunction and IR-ANH, implying that other fac- 
tors, such as unrecognized atrial pressure elevations, altered ANH metabolism, or 
alterations in as yet unknown modulators of ANH release, were operative in our 
patients. Alternatively, the autonomic nervous system may indeed play a role in ANH 
regulation but the measurements of autonomic function currently used, such as car- 
diovascular reflex tests and plasma catecholamine levels, may not be adequately sen- 
sitive to establish such a relationship. Furthermore, the study comprises a small group 
of subjects and the findings may not be universally applicable. Further study will be 
required in a larger group of subjects to determine whether more precise measure- 
ments of autonomic function such as transmyocardial catecholamine gradients or 
direct sympathetic nerve fiber recordings can establish a relationship. 
The clinical manifestations of elevated ANH levels in patients with diabetes mel- 
litus, if any, are unknown, It is interesting to speculate however as to whether the 
glomerular hyperfiltration characteristic of Type I patients [30,31] might be due in 
part to ANH, since ANH results in marked increases in glomerular filtration rates 
when administered to animals [5]. Glucagon and growth hormone have been impli- 
cated in the genesis of hyperfiltration [32,33], but the diurnal plasma concentrations 
of these two hormones were not found to be higher in diabetic patients with hyper- 
filtration than in those with normal glomerular filtration rate [34] and other factors 
may be influential. Although we did not observe increased glomerular filtration rates 
in all of the long-term diabetic patients with elevated ANH levels (Table II), further 
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